RE:RE:HOLD THE FCK UP HERE FOR A MINUTE!!!!!!!!CEO Blog: Why biOasis Matters 2015 has been a year of extraordinary accomplishment for biOasis, a year of success after success in studies that proved that the performance of Transcendpep, our peptide carrier designed to transport therapeutics across the blood-brain barrier, exceeded the performance of its base protein, p97 or Transcend. With exceptional results from the MedImmune Neuropathic Pain Program, the Brains for Brain MPS II study and from continuing studies with Trastuzumab (Herceptin) for the treatment of HER2+ brain metastases, biOasis in 2015 has completed the development stage of Transcendpepand has entered its long-awaited commercial phase. Because of these accomplishments, the commercial visibility of biOasis within the pharmaceutical industry has risen significantly. What we have shown to the industry is that our technology belongs here and that it has a serious opportunity to succeed. Consequently, the doors have opened for active discussions between biOasis and interested parties. We currently have over thirty companies talking to us about how our technology can be used within their organizations. Some of these companies are actively planning programs with us and some programs are already underway. A natural question that arises from all of this is why does biOasis matter right now? There are clear answers originality of our scientific approach, acceptance of the results of our programs, and the potentially stunning commercial opportunities that Transcendpeppresents to biOasis and its future partners. For decades, the accepted challenge presented to neuroscientists has been how to defeat the blood-brain barrier. Often overlooked in their efforts were natural processes that might be used as possible alternative solutions. What biOasis has developed is a means to transport therapeutic compounds across the blood-brain barrier by working with it, rather than to defeat it. The natural process developed by us has been accepted as being not only a novel solution that no others have developed, but also as a natural and correct approach. Most importantly, the economics of using Transcendpepversus the full-length sequence has made our technology more desirable and appealing than the more costly alternative of using the larger Transcend molecule, not to mention other technologies designed to defeat the blood-brain barrier. At biOasis, we arent shy about showing off our technology and our results. As such, we have invited companies to collaborate with us, to test our technology internally, and to see for themselves what the potential is for what we have worked so carefully to develop. For our company, this presents the possibility of significant commercial agreements and establishes biOasis as the clear industry front-runner, the one that matters, right now. From all of us at biOasis, we wish you and your families a very merry Christmas and, I know what will be a prosperous new year. Rob Hutchison is the CEO of biOasis Technologies Inc, a biopharmaceutical company focused on the delivery of therapeutics across the Blood-Brain Barrier and into the brain tissue with its proprietary Transcend Platform. BybiOasis Technologies Inc.|Wednesday, December 16, 2015|CEO Blog Share This Story, Choose Your Platform!